RAB19

Summary

RAB19 (RAB19, member RAS oncogene family, HGNC:19982) is a protein-coding gene on chromosome 7q34, encoding Ras-related protein Rab-19 (A4D1S5). The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes.

Predicted to enable GTPase activity. Predicted to be involved in autophagosome assembly and intracellular protein transport. Located in extracellular exosome.

Source: NCBI Gene 401409 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 52 total
• MANE Select transcript: NM_001008749

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19982
Approved symbol	RAB19
Name	RAB19, member RAS oncogene family
Location	7q34
Locus type	gene with protein product
Status	Approved
Aliases	RAB19B
Ensembl gene	ENSG00000146955
Ensembl biotype	protein_coding
Entrez	401409

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000356407, ENST00000537763, ENST00000897794, ENST00000897795, ENST00000897796, ENST00000897797, ENST00000924028, ENST00000924029

RefSeq mRNA: 1 — MANE Select: NM_001008749 NM_001008749

CCDS: CCDS34762

Canonical transcript exons

ENST00000537763 — 4 exons

Exon	Start	End
ENSE00001805995	140411874	140412057
ENSE00001843508	140404058	140404217
ENSE00001884985	140425882	140427974
ENSE00001956705	140407624	140407847

Expression profiles

Bgee: expression breadth broad, 73 present calls, max score 73.50.

FANTOM5 (CAGE): breadth broad, TPM avg 0.6418 / max 17.4386, expressed in 267 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
81505	0.3752	202
81506	0.2666	172

Top tissues by expression

118 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	73.50	gold quality
bone marrow cell	CL:0002092	70.73	gold quality
bone marrow	UBERON:0002371	69.87	gold quality
islet of Langerhans	UBERON:0000006	69.74	gold quality
rectum	UBERON:0001052	67.96	gold quality
pancreas	UBERON:0001264	67.49	gold quality
duodenum	UBERON:0002114	66.58	gold quality
body of pancreas	UBERON:0001150	66.01	gold quality
metanephros cortex	UBERON:0010533	65.14	gold quality
adult mammalian kidney	UBERON:0000082	64.51	gold quality
blood	UBERON:0000178	63.47	gold quality
kidney	UBERON:0002113	63.18	gold quality
cortex of kidney	UBERON:0001225	61.98	gold quality
colonic epithelium	UBERON:0000397	61.11	silver quality
right lobe of thyroid gland	UBERON:0001119	60.82	gold quality
pituitary gland	UBERON:0000007	59.81	gold quality
left lobe of thyroid gland	UBERON:0001120	59.67	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	58.88	gold quality
thyroid gland	UBERON:0002046	58.78	gold quality
tonsil	UBERON:0002372	58.66	gold quality
transverse colon	UBERON:0001157	58.42	gold quality
lymph node	UBERON:0000029	58.39	gold quality
adenohypophysis	UBERON:0002196	57.84	gold quality
vermiform appendix	UBERON:0001154	57.77	gold quality
placenta	UBERON:0001987	56.60	gold quality
granulocyte	CL:0000094	56.52	gold quality
gall bladder	UBERON:0002110	55.47	gold quality
small intestine	UBERON:0002108	54.63	gold quality
small intestine Peyer’s patch	UBERON:0003454	53.58	gold quality
stomach	UBERON:0000945	52.08	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.79

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

6 targeting RAB19, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-6744-3P	99.22	64.41	972
HSA-MIR-4757-5P	99.12	64.51	981
HSA-MIR-6781-3P	97.44	66.85	970
HSA-MIR-2682-3P	97.10	66.16	840

Literature-anchored findings (GeneRIF, showing 2)

• N6-methyladenosine (m6A)-mediated up-regulation of long noncoding RNA LINC01320 promotes the proliferation, migration, and invasion of gastric cancer via miR495-5p/RAB19 axis. (PMID:34288797)
• WDR38, a novel equatorial segment protein, interacts with the GTPase protein RAB19 and Golgi protein GM130 to play roles in acrosome biogenesis. (PMID:37635409)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
		ENSDARG00000099205
danio_rerio	RAB19	ENSDARG00000101150
mus_musculus	Rab19	ENSMUSG00000029923
rattus_norvegicus	Rab19	ENSRNOG00000009030

Paralogs (68): RAB27B (ENSG00000041353), RAB27A (ENSG00000069974), RAB7A (ENSG00000075785), RABL2B (ENSG00000079974), RAB21 (ENSG00000080371), RAB10 (ENSG00000084733), RAB18 (ENSG00000099246), RAB36 (ENSG00000100228), IFT27 (ENSG00000100360), RAB40AL (ENSG00000102128), RAB11A (ENSG00000103769), RAB2A (ENSG00000104388), RAB3D (ENSG00000105514), RAB3A (ENSG00000105649), RAB5C (ENSG00000108774), RAB34 (ENSG00000109113), RAB5B (ENSG00000111540), RAB35 (ENSG00000111737), RAB23 (ENSG00000112210), DNAJC27 (ENSG00000115137), RAB29 (ENSG00000117280), RAB32 (ENSG00000118508), RAB14 (ENSG00000119396), RAB9B (ENSG00000123570), RAB9A (ENSG00000123595), RAB38 (ENSG00000123892), RAB22A (ENSG00000124209), RAB17 (ENSG00000124839), RAB2B (ENSG00000129472), RAB25 (ENSG00000132698), RAB33A (ENSG00000134594), RAB30 (ENSG00000137502), RAB1A (ENSG00000138069), RAB20 (ENSG00000139832), RAB15 (ENSG00000139998), RAB40B (ENSG00000141542), RAB13 (ENSG00000143545), RABL2A (ENSG00000144134), RAB5A (ENSG00000144566), RAB41 (ENSG00000147127)

Protein

Protein identifiers

Ras-related protein Rab-19 — A4D1S5 (reviewed: A4D1S5)

All UniProt accessions (1): A4D1S5

UniProt curated annotations — full annotation on UniProt →

Function. The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different set of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion.

Subcellular location. Cell membrane.

Activity regulation. Regulated by guanine nucleotide exchange factors (GEFs) which promote the exchange of bound GDP for free GTP. Regulated by GTPase activating proteins (GAPs) which increase the GTP hydrolysis activity. Inhibited by GDP dissociation inhibitors (GDIs).

Domain organisation. Switch 1, switch 2 and the interswitch regions are characteristic of Rab GTPases and mediate the interactions with Rab downstream effectors. The switch regions undergo conformational changes upon nucleotide binding which drives interaction with specific sets of effector proteins, with most effectors only binding to GTP-bound Rab.

Similarity. Belongs to the small GTPase superfamily. Rab family.

Isoforms (2)

UniProt ID	Names	Canonical?
A4D1S5-1	1	yes
A4D1S5-2	2

RefSeq proteins (1): NP_001008749* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR048040	Rab19/43	Family
IPR050209	Rab_GTPases_membrane_traffic	Family

Pfam: PF00071

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (29 total): binding site 21, short sequence motif 2, lipid moiety-binding region 2, chain 1, modified residue 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A4D1S5-F1	83.68	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (21): 42; 43; 44; 45; 49; 49; 72; 75; 130; 131; 133; 161 …

Post-translational modifications (3): 217, 215, 217

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8873719	RAB geranylgeranylation

MSigDB gene sets: 93 (showing top): GSE45365_NK_CELL_VS_BCELL_DN, GOBP_VACUOLE_ORGANIZATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_MACROAUTOPHAGY, GOBP_ORGANELLE_ASSEMBLY, GOBP_AUTOPHAGOSOME_ORGANIZATION, ZHENG_BOUND_BY_FOXP3, MARSON_BOUND_BY_FOXP3_STIMULATED, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, GOMF_GTPASE_ACTIVITY, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, CHEN_METABOLIC_SYNDROM_NETWORK, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, MIKKELSEN_ES_ICP_WITH_H3K4ME3, LI_INDUCED_T_TO_NATURAL_KILLER_UP

GO Biological Process (2): autophagosome assembly (GO:0000045), intracellular protein transport (GO:0006886)

GO Molecular Function (7): GTPase activity (GO:0003924), G protein activity (GO:0003925), GTP binding (GO:0005525), metal ion binding (GO:0046872), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (4): plasma membrane (GO:0005886), endomembrane system (GO:0012505), extracellular exosome (GO:0070062), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
Atg12 activating enzyme activity	1
protein-phosphatidylethanolamide deconjugating activity	1
Atg12 conjugating enzyme activity	1
Atg12 ligase activity	1
organelle assembly	1
Atg1/ULK1 kinase complex assembly	1
autophagosome organization	1
intracellular protein localization	1
protein transport	1
intracellular transport	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
molecular function regulator activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
membrane	1
cell periphery	1
vacuole	1
plasma membrane	1
extracellular vesicle	1

Protein interactions and networks

STRING

1279 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAB19	GOLGA1	Q92805	572
RAB19	RAB18	Q9NP72	519
RAB19	TBC1D4	O60343	490
RAB19	ARMH1	Q6PIY5	489
RAB19	RAB6A	P20340	485
RAB19	RAB30	Q15771	469
RAB19	RAB2A	P08886	450
RAB19	RAB11A	P24410	426
RAB19	RAB4A	P20338	423
RAB19	RAB39A	Q14964	415
RAB19	FAM162B	Q5T6X4	397
RAB19	F2RL2	O00254	387
RAB19	STX6	O43752	380
RAB19	TRAPPC1	Q9Y5R8	348
RAB19	COL6A5	A8TX70	338

IntAct

19 interactions, top by confidence:

A	B	Type	Score
RAB19	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.560
RAB19	RABIF	psi-mi:“MI:0915”(physical association)	0.560
VCAN	RAB19	psi-mi:“MI:0915”(physical association)	0.560
RAB19	LSM11	psi-mi:“MI:0915”(physical association)	0.560
RAB10	RAB19	psi-mi:“MI:0914”(association)	0.350
GOLM1	RAB19	psi-mi:“MI:0914”(association)	0.350
	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
RAB33A	RAB19	psi-mi:“MI:0914”(association)	0.350
RAB19	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.000
RABIF	RAB19	psi-mi:“MI:0915”(physical association)	0.000
VCAN	RAB19	psi-mi:“MI:0915”(physical association)	0.000
LSM11	RAB19	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (11): VDAC3 (Co-fractionation), TOMM40 (Co-fractionation), VDAC1 (Co-fractionation), TOMM5 (Co-fractionation), RAB19 (Two-hybrid), LSM11 (Two-hybrid), RABIF (Two-hybrid), KRTAP10-8 (Two-hybrid), RAB19 (Proximity Label-MS), RAB19 (Affinity Capture-MS), RAB19 (Affinity Capture-MS)

ESM2 similar proteins: A4D1S5, O13876, O80501, P05714, P10948, P10949, P20337, P20338, P34213, P35289, P35293, P35294, P51152, P51159, P56371, P62823, P90726, Q05976, Q0IIG8, Q15771, Q17QB7, Q18969, Q1HE58, Q28IZ3, Q2TBH7, Q32NQ0, Q3ZC27, Q53B90, Q54E92, Q55FK2, Q5EB77, Q5KTJ7, Q5M7U5, Q5R5H5, Q63941, Q68EK7, Q6DHC1, Q6PHI9, Q8CG50, Q923S9

Diamond homologs: A4D1S5, A4FV54, F1PTE3, O04486, O24466, O76173, P01123, P10536, P11620, P16976, P17609, P20790, P20791, P22125, P22128, P28186, P28188, P31584, P33723, P34139, P34140, P35280, P35286, P35294, P36410, P36863, P40392, P51153, P51156, P53994, P55258, P59279, P61006, P61007, P61019, P61028, P61105, P62820, P62821, P62822

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

621 predictions. Top by Δscore:

Variant	Effect	Δscore
7:140411872:A:AG	acceptor_gain	1.0000
7:140411873:G:GT	acceptor_gain	1.0000
7:140411873:GA:G	acceptor_gain	1.0000
7:140411873:GAT:G	acceptor_gain	1.0000
7:140411873:GATGC:G	acceptor_gain	1.0000
7:140412041:G:GA	donor_gain	1.0000
7:140412053:GATTG:G	donor_gain	1.0000
7:140412055:TTGGT:T	donor_loss	1.0000
7:140412058:G:GG	donor_gain	1.0000
7:140425880:A:AG	acceptor_gain	1.0000
7:140425880:AGG:A	acceptor_loss	1.0000
7:140425881:G:GG	acceptor_gain	1.0000
7:140425881:GGA:G	acceptor_gain	1.0000
7:140425881:GGAA:G	acceptor_gain	1.0000
7:140404213:GACAG:G	donor_gain	0.9900
7:140404219:T:G	donor_loss	0.9900
7:140407622:A:AG	acceptor_gain	0.9900
7:140407623:G:GG	acceptor_gain	0.9900
7:140407797:G:GT	donor_gain	0.9900
7:140407812:G:GG	donor_gain	0.9900
7:140411861:T:TA	acceptor_gain	0.9900
7:140411872:AGAT:A	acceptor_gain	0.9900
7:140411873:GATG:G	acceptor_gain	0.9900
7:140412058:GTAT:G	donor_loss	0.9900
7:140412059:T:G	donor_loss	0.9900
7:140425880:AG:A	acceptor_gain	0.9900
7:140425881:GG:G	acceptor_gain	0.9900
7:140425881:GGAAA:G	acceptor_gain	0.9900
7:140407623:GTT:G	acceptor_gain	0.9800
7:140407623:GTTCT:G	acceptor_gain	0.9800

AlphaMissense

1435 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:140407734:A:C	K30Q	0.999
7:140407798:G:A	G51E	0.999
7:140411883:T:A	W71R	0.999
7:140411883:T:C	W71R	0.999
7:140411887:A:C	D72A	0.999
7:140411887:A:T	D72V	0.999
7:140411907:T:C	F79L	0.999
7:140411909:C:A	F79L	0.999
7:140411909:C:G	F79L	0.999
7:140425888:A:T	K131I	0.999
7:140407717:G:A	G24E	0.998
7:140407717:G:T	G24V	0.998
7:140407732:G:A	G29E	0.998
7:140407806:T:C	F54L	0.998
7:140407808:T:A	F54L	0.998
7:140407808:T:G	F54L	0.998
7:140411886:G:C	D72H	0.998
7:140411887:A:G	D72G	0.998
7:140411888:C:A	D72E	0.998
7:140411888:C:G	D72E	0.998
7:140411907:T:A	F79I	0.998
7:140407716:G:T	G24W	0.997
7:140407731:G:T	G29W	0.997
7:140407732:G:T	G29V	0.997
7:140407734:A:G	K30E	0.997
7:140407735:A:T	K30M	0.997
7:140407736:G:C	K30N	0.997
7:140407736:G:T	K30N	0.997
7:140411885:G:C	W71C	0.997
7:140411885:G:T	W71C	0.997

dbSNP variants (sampled 300 via entrez): RS1000182796 (7:140419430 C>T), RS1000263715 (7:140418737 T>G), RS1000401217 (7:140418524 C>G,T), RS1000423119 (7:140425031 A>G), RS1000612474 (7:140415105 T>C), RS1000701681 (7:140412460 A>G,T), RS1000732939 (7:140420091 G>C), RS1000892957 (7:140403872 G>A,C), RS1000899844 (7:140413888 T>C), RS1001163432 (7:140426229 C>G), RS1001222690 (7:140419883 T>C), RS1001253631 (7:140420264 T>C), RS1001411305 (7:140427016 AT>A,ATT), RS1001669964 (7:140413000 C>G), RS1001693881 (7:140425585 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (2): non-syndromic syndactyly (MONDO:0019530), primary ovarian failure (MONDO:0005387)

Orphanet (2): Non-syndromic syndactyly (Orphanet:90025), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009028_31	Adverse response to drug	3.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009658	adverse effect

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

6 total (human), top 6 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression, increases methylation	3
CGP 52608	affects binding, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	affects expression	1

Clinical trials (associated diseases)

79 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04564430	PHASE4	UNKNOWN	Clonidine for Tourniquet-related Pain in Children
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT03107546	Not specified	COMPLETED	Comparison of Scar Formation in Syndactyly Release Surgery With Full Thickness Skin Graft Versus Skin Graft Substitute
NCT06239064	Not specified	ACTIVE_NOT_RECRUITING	Early Genetic Identification of Obesity
NCT07596862	Not specified	COMPLETED	Remote Assesment of Functional Sequelae in Patients Operated for Congenital Syndactyly
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial